Early strong anticholinergic initiation and 30-day mortality in older inpatients with dementia: a target trial emulation
This target trial emulation using MIMIC-IV data found that the extreme rarity of strong anticholinergic initiation in older inpatients with dementia prevented a clinically interpretable estimate of 30-day mortality, while a separate landmark analysis yielded imprecise results that could not establish safety or causality.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Every year, millions of older adults with dementia are admitted to hospitals for acute illness. For many of these patients, the hospital stay itself becomes a new health challenge. The stress of a new environment, the disruption of routine, and the introduction of multiple new medications can trigger a sudden, severe confusion known as delirium. Among the many drugs given in hospitals, a specific class called strong anticholinergics is often scrutinized. These medicines, which block a natural chemical in the brain to treat issues like bladder control or nausea, are known to carry risks for older people. They can worsen confusion, increase the chance of delirium, and potentially lead to death. While doctors know these drugs can be dangerous in general, a critical question remains unanswered for those already hospitalized with dementia: if a patient is admitted and does not yet have these drugs on their list, is it safe to start one of them during that first two days of care?
To answer this, researchers turned to a massive collection of real-world hospital records from Boston, spanning over a decade. They treated this data as if it were a controlled experiment, a method known as a target trial emulation. In a perfect world, doctors would randomly assign some patients to start a strong anticholinergic within 48 hours of admission and others to avoid it entirely, then watch who survived the next month. Since such a trial has not been done, the researchers tried to reconstruct that scenario using the electronic health records of 3,706 hospital admissions. They looked specifically at patients over 65 with documented dementia, checking to see if a confirmed dose of a strong anticholinergic (excluding a specific type used for motion sickness) was given within the first two days. They compared the outcomes of those who received the drug against those who did not, focusing on whether the patient died within 30 days of admission.
The researchers found that the data simply did not contain enough information to answer the question. In the entire group of nearly 3,700 admissions, only 47 patients actually received a confirmed dose of the specific strong anticholinergic they were studying within that critical 48-hour window. This extreme rarity meant that when the researchers tried to use statistical methods to balance the groups and make a fair comparison, the math broke down. The group of patients who started the drug was so small and so different from the rest that the researchers could not produce a reliable estimate of the risk. It was as if they were trying to measure the average height of a specific type of rare bird by looking at a forest of millions of other birds; the few rare ones they found were not enough to draw a conclusion about the whole species. Consequently, the study could not determine whether starting the drug early increased the risk of death, decreased it, or had no effect at all.
Because the main question remained unanswered, the team tried a different approach. They looked only at the patients who were still alive and in the hospital 48 hours after admission, comparing those who had received the drug during that first two days against those who had not. This group was larger, and the statistical balance between the two sides was much better. The results here showed no clear difference in death rates between the two groups, but the numbers were too wide and uncertain to be useful. The data allowed for the possibility that the drug could be harmful, but it also allowed for the possibility that it was safe or even beneficial. The uncertainty was so great that the study could not confirm safety, nor could it prove harm.
The ultimate conclusion is that the current hospital records, despite being vast and detailed, are not sufficient to guide doctors on this specific decision. The study explicitly rules out the idea that we can use this data to reassure doctors that it is safe to start these drugs, or to warn them that it is definitely dangerous. The lack of a clear answer is not a finding of safety; it is a finding of missing information. The researchers noted that for a future study to succeed, it would need to recruit patients from many different hospitals and ensure that the administration of these drugs is carefully verified. Until such a study is conducted, doctors must continue to rely on existing guidelines that generally advise caution with these medications for older patients with dementia, rather than any new evidence from this analysis. The question of whether to start a strong anticholinergic in the first two days of a hospital stay for a patient with dementia remains an unresolved safety decision.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.